129 related articles for article (PubMed ID: 24439565)
1. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Jaglal MV; Duong VH; Bello CM; Al Ali NH; Padron E; Fernandez HF; List AF; Lancet JE; Komrokji RS
Leuk Res; 2014 Apr; 38(4):443-6. PubMed ID: 24439565
[TBL] [Abstract][Full Text] [Related]
2. Cladribine in the treatment of acute myeloid leukemia.
Robak T; Wierzbowska A
Leuk Res; 2014 Apr; 38(4):425-7. PubMed ID: 24485872
[No Abstract] [Full Text] [Related]
3. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
4. Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Ruan M; Liu LP; Zhang AL; Quan Qi B; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Cancer Med; 2021 Feb; 10(3):956-964. PubMed ID: 33491298
[TBL] [Abstract][Full Text] [Related]
5. Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series.
Zhang J; Sun Y; Zhang X; Long B; Lu Y; Li X
Transplant Proc; 2018; 50(1):246-249. PubMed ID: 29407318
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
Price SL; Lancet JE; George TJ; Wetzstein GA; List AF; Ho VQ; Fernandez HF; Pinilla-Ibarz J; Kharfan-Dabaja MA; Komrokji RS
Leuk Res; 2011 Mar; 35(3):301-4. PubMed ID: 21109304
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
11. CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
Seiter K; Ahmed N; Shaikh A; Baskind P; Liu D
Leuk Res; 2016 Jul; 46():74-8. PubMed ID: 27151544
[TBL] [Abstract][Full Text] [Related]
12. Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Walti CS; Halpern AB; Xie H; Kiem ES; Chung EL; Schonhoff KG; Huebner EM; Delaney C; Liu C; Pergam SA; Cheng GS; Kimball LE; Leisenring WM; Boeckh M; Walter RB; Hill JA
Leukemia; 2023 Feb; 37(2):298-307. PubMed ID: 36509892
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'.
Scheckel CJ; Meyer M; Betcher JA; Al-Kali A; Foran J; Palmer J
Leuk Res; 2020 Mar; 90():106300. PubMed ID: 32018118
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
Palmieri R; Othus M; Halpern AB; Percival MM; Godwin CD; Becker PS; Walter RB
J Clin Oncol; 2020 Dec; 38(35):4163-4174. PubMed ID: 33030979
[TBL] [Abstract][Full Text] [Related]
15. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience.
Martin MG; Welch JS; Augustin K; Hladnik L; DiPersio JF; Abboud CN
Clin Lymphoma Myeloma; 2009 Aug; 9(4):298-301. PubMed ID: 19717379
[TBL] [Abstract][Full Text] [Related]
16. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Halpern AB; Othus M; Huebner EM; Scott BL; Hendrie PC; Percival MM; Becker PS; Smith HA; Oehler VG; Orozco JJ; Cassaday RD; Gardner KM; Chen TL; Buckley SA; Orlowski KF; Anwar A; Estey EH; Walter RB
Haematologica; 2019 Apr; 104(4):e143-e146. PubMed ID: 30409798
[No Abstract] [Full Text] [Related]
18. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Bolaños-Meade J; Guo C; Gojo I; Karp JE
Leuk Res; 2004 Jun; 28(6):571-7. PubMed ID: 15120933
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
Wang L; Xu J; Tian X; Lv T; Yuan G
Acta Haematol; 2019; 141(1):43-53. PubMed ID: 30517910
[TBL] [Abstract][Full Text] [Related]
20. Salvaging AML with CLAG: novel option, or more of the same?
Wei A; Teh TC
Leuk Res; 2011 Mar; 35(3):297-8. PubMed ID: 21074270
[No Abstract] [Full Text] [Related]
[Next] [New Search]
